Natural Killer Cell Therapies Competitive Landscape Technology & Pipeline Analysis report provides comprehensive insights on the therapeutic development

Natural Killer Cell Therapies Competitive Landscape and Pipeline Analysis

<h2>Overview</h2>

Natural killer cells, also known as NK Cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. Natural Killer Cell have cytotoxic small granules which contain special proteins such as perforins and proteases are known as granzymes in their cytoplasm. Perforins form pores in the cell membrane of the target cell through which the granzymes and associated molecules induce apoptosis. Natural Killer Cell are derived from the common lymphoid progenitor cells (lymphoblasts), which also generate B and T lymphocytes. They differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus, where they then enter into the bloodstream.

&nbsp;

&ldquo;Natural Killer Cell Therapies - Competitive Landscape, Technology and Pipeline Analysis, 2021&rdquo; report provides comprehensive insights on the therapeutic development for this mechanism of action. The objective of the report is to establish an understanding of the therapeutic competitive landscape for Natural Killer Cell Therapies, including the pipeline products in this space. It further offers comparative pipeline analysis with their drug profiles at various stages of development covering Phase III, Phase II, Phase I, Preclinical and Discovery. Information on company collaborations, agreements, acquisitions, Natural Killer Cell Therapies licensing, deals, and other development activities is also involved in this report Therapeutics assessment of active pipeline drugs by stage, therapy type, route of administration, and molecule type is also covered in this report. It features the inactive pipeline products and highlights currently undergoing institutional research in this area. The report provides the information related to several technologies in development of the molecules based on the Natural Killer Cell Therapies mechanism. The report provides the understanding of the unmet needs of the Natural Killer Cell Therapies market.

&nbsp;&nbsp;&nbsp;

Future competitive landscape of Natural Killer Cell Therapies is estimated to be very strong. Key emerging drugs including Nektar Therapeutics&rsquo; NKTR-214, Five Prime Therapeutics&rsquo; Bemarituzumab, Affimed Therapeutics&rsquo; AFM-13, Green Cross Corporation&rsquo;s MG 4101 and others are going to be Blockbuster in the upcoming years.

<h2>Natural Killer Cell Therapies Report Key Features </h2>

The report provides insights into:

<ul>
	<li>A number of companies developing therapies of Natural Killer Cell Therapies with aggregate therapies developed by each company for the same.</li>
	<li>Detailed profiles of therapeutic candidates in nonclinical stage, early-stage, mid-stage and late-stage of development for Natural Killer Cell Therapies.</li>
	<li>Analyses key players involved in Natural Killer Cell Therapies targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.</li>
	<li>Active pipeline therapies assessment under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.</li>
	<li>Detail analysis of collaboration (company&ndash;company collaborations and company&ndash;academia collaborations), licensing agreement and financing details for future developments of Natural Killer Cell Therapies.</li>
	<li>Detailed information regarding the technologies developed for the Natural Killer Cell Therapies.</li>
	<li>The report is built using data and information traced from the researcher&#39;s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.</li>
</ul>

&nbsp;

<h3>Natural Killer Cell Therapies Analytical Perspective by DelveInsight</h3>

&nbsp;

&bull; In-depth Natural Killer Cell Therapies Analysis: Assessment of Products 

This report provides an in-depth commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, agreements, licensing, and acquisition &ndash; deal value trends related to Natural Killer Cell Therapies. The sub-segmentation is described in the report which provides Natural Killer Cell Therapies company&ndash;company collaborations (licensing/partnering), Natural Killer Cell Therapies company&ndash;academia collaborations, and acquisition analysis in both graphical and tabulated form.

&nbsp;

&bull; Natural Killer Cell Therapies Clinical Assessment of Products

The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this mechanism of action.

<h2>&nbsp;</h2>

<h3>Scope of the Natural Killer Cell Therapies Report</h3>

&nbsp;

<ul>
	<li>The Natural Killer Cell Therapies report provides an overview of this mechanism of action, role, significance, pathway, types, and clinical application of Natural Killer Cell Therapies.</li>
	<li>Therapeutic Assessment: Therapeutic pipeline activity and assessment of the products by development stage, product type, route of administration, molecule type, and MOA the complete product development cycle, including all clinical and nonclinical stages.</li>
	<li>It comprises of detailed profiles of therapeutic products for Natural Killer Cell Therapies with key coverage of developmental activities, including collaborations, agreements, licensing, mergers and acquisition, funding, designations, technology and other product-related details.</li>
	<li>In-depth Natural Killer Cell Therapies research and development progress and trial details results wherever available, are also included in the pipeline study.</li>
	<li>Coverage of dormant and discontinued pipeline projects along with the reasons if available across Natural Killer Cell Therapies.</li>
	<li>It also includes patent expiry details impact on market after expiry.</li>
	<li>Key topics covered include strategic competitor assessment, detailed drug profiles of marketed and emerging products, therapeutic assessment of drugs by phase, route of administration, molecule type and product type, detailed analysis of the technologies related to Natural Killer Cell Therapies opportunities, unmet needs, market growth factors, barriers and challenges of the Natural Killer Cell Therapies market.</li>
</ul>

<table border="1" cellpadding="10" cellspacing="0" width="">
	<tbody>
		<tr>
			<td height="" width="">
			Company&nbsp;
			</td>
			<td height="" width="">
			Phase
			</td>
			<td height="" width="">
			Intervention
			</td>
			<td height="" width="">
			Indication
			</td>
			<td height="" width="">
			Trial Identifier
			</td>
			<td height="" width="">
			Trial Status
			</td>
		</tr>
		<tr>
			<td height="" width="">
			NantKwest&nbsp;
			</td>
			<td height="" width="">
			II
			</td>
			<td height="" width="">
			Avelumab; N-803; haNK
			</td>
			<td height="" width="">
			Merkel Cell Carcinoma
			</td>
			<td height="" width="">
			NCT03853317
			</td>
			<td height="" width="">
			Recruiting
			</td>
		</tr>
		<tr>
			<td height="" width="">
			Artiva Biotherapeutics
			</td>
			<td height="" width="">
			I/II
			</td>
			<td height="" width="">
			AB-101
			</td>
			<td height="" width="">
			Non-Hodgkin Lymphoma
			</td>
			<td height="" width="">
			NCT04673617
			</td>
			<td height="" width="">
			Recruiting
			</td>
		</tr>
		<tr>
			<td height="" width="">
			Coronado Biosciences
			</td>
			<td height="" width="">
			I
			</td>
			<td height="" width="">
			CNDO-109-AANK Cells
			</td>
			<td height="" width="">
			Acute Myeloid Leukemia
			</td>
			<td height="" width="">
			NCT01520558
			</td>
			<td height="" width="">
			Unknown
			</td>
		</tr>
		<tr>
			<td height="" width="">
			Affimed
			</td>
			<td height="" width="">
			I
			</td>
			<td height="" width="">
			NK cells combined with the antibody AFM13 (AFM13-NK) and AFM13 alone
			</td>
			<td height="" width="">
			CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
			</td>
			<td height="" width="">
			NCT04074746
			</td>
			<td height="" width="">
			Recruiting
			</td>
		</tr>
		<tr>
			<td height="" width="">
			Bristol-Myers Squibb
			</td>
			<td height="" width="">
			I
			</td>
			<td height="" width="">
			Lirilumab; Nivolumab; Ipilimumab
			</td>
			<td height="" width="">
			Advanced Cancer
			</td>
			<td height="" width="">
			NCT03203876
			</td>
			<td height="" width="">
			Active, not recruiting
			</td>
		</tr>
		<tr>
			<td height="" width="">
			Celularity Incorporated
			</td>
			<td height="" width="">
			I
			</td>
			<td height="" width="">
			CYNK-001
			</td>
			<td height="" width="">
			Glioblastoma Multiforme
			</td>
			<td height="" width="">
			NCT04489420
			</td>
			<td height="" width="">
			Recruiting
			</td>
		</tr>
	</tbody>
</table>

<h3>Natural Killer Cell Therapies Report Highlights</h3>

&nbsp;

<ul>
	<li>In March 2020, Kuur Therapeutics announced the launch of its new business in partnership with Baylor College of Medicine and Baylor&rsquo;s Center for Cell and Gene Therapy. Houston-based Kuur Therapeutics will advance the work of its predecessor, Cell Medica, to develop anti-cancer therapies using its innovative chimeric antigen receptor natural killer T cell (CAR-NKT) therapy platform&nbsp;&nbsp;&nbsp;</li>
	<li>In April 2020, Fate Therapeutics announced a global collaboration and option agreement with Janssen Biotech.Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets. The Company will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates.&nbsp;&nbsp;&nbsp;</li>
	<li>Acepodia&rsquo;s proprietary ACC (Antibody-Cell Conjugation) technology platform attaches tumor targeting antibodies to the surface of a novel and proprietary human natural killer cell line (oNatural Killer Cell Therapies). The ability of antibody directed Natural Killer Cell Therapies to treat human cancers offers a new and powerful therapeutic approach to treating human cancers, especially those with metastatic potential.</li>
	<li>In January 2020, Acepodia announced it has received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate a Phase I clinical study of its natural killer (NK) cell therapy and lead drug candidate ACE1702 in patients with HER2-expressing solid tumors.</li>
</ul>

<h3>&nbsp;</h3>

<h3>Natural Killer Cell Therapies&nbsp;Companies Mentioned</h3>

&nbsp;

● Abivax

● Affimed Therapeutics

● Altor Bioscience Corporation

● Ambicion

● Apceth Biopharma

● Bellicum Pharmaceuticals

● Biothera Pharmaceuticals

● Bright Path Biotherapeutics

● Bristol-Myers Squibb

● Cantargia

● CARsgen therapeutics

● Celgene Corporation/Celularity

● Cell Medica

● CellProtect Nordic Pharmaceuticals

● Celularity

● Ceylad Therapeutics

● CureTech

● CytoVac

● Dragonfly Therapeutics

● Dynavax

● Fate Therapeutics

● Feldan Therapeutics

● Five Prime Therapeutics

● Fortress Biotech

● GamidaCell

● Glycostem Therapeutics (IPD Therapeutic)

● Green Cross Corporation

● GT Biopharma

● iCell Gene Therapeutics

● Innate Pharma

● Multimmune GmbH

● NantKwest

● Nektar Therapeutics

● PersonGen BioTherapeutics (Suzhou)

● Shanghai Houchao Biotechnology

● Shanghai iCELL Biotechnology

● Sorrento Therapeutics

● Surface Oncology

● SYNIMMUNE

● Vycellix

● Xyphos

● ZIOPHARM Oncology

● Nohla Therapeutics

● Kiadis Pharma

● Nkarta Therapeutics

● Acepodia

● Allife Medical Science and Technology

● Asclepius Technology Company

● cellid

And many more &hellip;

<h2>&nbsp;</h2>

<h3>Natural Killer Cell Therapies Key Questions Answered In The Report</h3>

&nbsp;

<ul>
	<li>What are Natural Killer Cell Therapies, their role and significance in the treatment of disease conditions?</li>
	<li>How many therapies are developed by each company for Natural Killer Cell Therapies to treat disease conditions?</li>
	<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), mergers and acquisitions, licensing activities related to the Natural Killer Cell Therapies therapies?</li>
	<li>Which are the dormant and discontinued products and the reasons for dormancy and discontinuation?</li>
	<li>What is the unmet need for current therapies developed on the basis of this mechanism of action?</li>
	<li>What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?</li>
	<li>What are the clinical studies going on for Natural Killer Cell Therapies and their status?</li>
	<li>What are the current and upcoming technologies for the Natural Killer Cell Therapies?</li>
</ul>

1. Report Introduction

2. Natural Killer Cell Therapies

2.1.&nbsp;Natural Killer Cell Therapies Overview

2.2.&nbsp;Natural Killer Cell Therapies Types

2.3.&nbsp;Natural Killer Cell Therapies Structure

2.4.&nbsp;Natural Killer Cell Therapies Mechanism of Action

2.5.&nbsp;Natural Killer Cell Therapies Application

3. Competitive Landscape

4. Natural Killer Cell Therapies - DelveInsight&rsquo;s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Natural Killer Cell Therapies Companies Collaborations, Licensing, Acquisition &ndash; Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Natural Killer Cell Therapies Collaboration Deals

4.1.2.1. Company&ndash;Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Company&ndash;University Collaborations (Licensing/Partnering) Analysis

4.1.2.3. Natural Killer Cell Therapies Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Stage of Development

5.1.2. Assessment by Product Type (Mono/Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Pipeline Therapeutics

6.1. Comparative Analysis

7. Late-Stage Products (Phase-III)

8. Mid-Stage Products (Phase-II)

9. Early-Stage Products (Phase-I)

10. Preclinical and Discovery Stage Products

11. Natural Killer Cell Therapies Emerging Drug Profiles

11.1. NKTR-214: Nektar Therapeutics

11.1.1. Product Description

11.1.2. Research and Development

11.1.2.1. Clinical Studies

11.1.3. Product Development Activities

11.1.4. Tabulated Product Summary

11.1.4.1. General Description Table

Many more drugs with detailed profiles provided in the report &hellip;

12. Natural Killer Cell Therapies Key Companies

13. Natural Killer Cell Therapies Key Products

14. Inactive Products

14.1. Dormant Products

14.1.1. Reason for Dormancy

14.2. Discontinued Products

14.2.1. Reason for Discontinuation

15. Natural Killer Cell Therapies - Unmet Needs

16. Natural Killer Cell Therapies - Future Perspectives and Conclusion

17. Natural Killer Cell Therapies Analyst Views

18. Appendix

19. Report Methodology

19.1. Secondary Research

19.2. Expert Panel Validation

Natural Killer Cell Therapies Competitive Landscape

Natural Killer Cell Therapies Competitive Landscape, Technology and Pipeline Analysis, 2021

“NK Cells - Competitive Landscape, Technology and Pipeline Analysis, 2021” report provides comprehensive insights on the therapeutic development for this mechanism of action.

Customize Reports As Per Your Needs